Effects of Bolus Surfactant Therapy on Peripheral Perfusion Index and Tissue Carbon Monoxide

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Respiratory Distress Syndrome
Interventions
DRUG

exogenous surfactant

Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached \> 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.

Trial Locations (1)

35100

Ege University Children's Hospital Neonatal Intesive Care Unit, Izmir

All Listed Sponsors
lead

Ege University

OTHER

NCT01923844 - Effects of Bolus Surfactant Therapy on Peripheral Perfusion Index and Tissue Carbon Monoxide | Biotech Hunter | Biotech Hunter